image-150-64c8cd514b55a.webp

image-151-64c8cd518a917.webp

group-1000002623-64c8cd4f8d576.webp

image-146-64c8cd50567b2.webp

image-147-64c8cd501e463.webp

image-148-64c8cd50b2c5c.webp

image-149-64c8cd50d627e.webp

BBC-Logo.webp

The-Independent-Logo.webp

Featured in

AI biomarkers, built for real-world impact and clinical trials. Meet us at ASCO 2026 | Booth #IH12.

Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025

Qure.ai partners with Microsoft to increase access to its lung cancer detection and management suite in the U.S.

qTrack

Qure.ai, a prominent medtech company based in Bombay, India, has recently achieved a significant milestone by obtaining clearance from the U.S. Food and Drug Administration (FDA) for its artificial intelligence-driven CT scan tool, qER. This approval marks a historical moment, as Qure.ai becomes the first company from India to receive FDA approval for a medical imaging product, positioning it at the forefront of global healthcare technology.

qER is a sophisticated triage and notification system designed to revolutionize the detection and prioritization of critical head scan abnormalities. By leveraging advanced artificial intelligence, the system identifies potentially life-threatening conditions, such as midline shifts, cranial fractures, and intracranial hemorrhages, that require immediate medical intervention. Its ability to pinpoint these injuries with exceptional accuracy allows for faster decision-making in emergency care, potentially preventing the discharge of individuals with undetected fatal injuries. With qER, medical professionals are empowered to triage nearly any significant anomaly detected in a routine CT scan, ensuring that urgent cases receive the attention they need.

The underlying AI imaging technology of qER is not merely a technical innovation but a significant step forward in addressing the limitations of medical infrastructure in many regions. By automating the interpretation of complex scans, qER reduces the burden on overworked radiology departments, allowing for quicker and more accurate diagnoses. This has the potential to dramatically lower fatality rates caused by misdiagnosed or overlooked injuries, which are often due to the lack of timely access to specialized care.

Operating from its U.S. headquarters in New York, Qure.ai has rapidly expanded its global footprint, incorporating deep learning algorithms to provide AI-driven solutions for a variety of medical imaging needs, including X-rays, MRI scans, and Covid-19 progression monitoring. The company's portfolio has grown to serve over 20 countries, reflecting its commitment to enhancing diagnostic accuracy and improving patient outcomes worldwide. As Qure.ai continues to push the boundaries of AI in healthcare, it is poised to remain a leader in medical technology, delivering life-saving solutions on a global scale.

thumbnail_32.png

32.png

Qure.ai CT scan solution earns India-first FDA approval

Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product&nbsp;‘qER’. The US Food and Drug Administration’s decision covers four critical markers identified by Qure.ai’s emergency room product. Now the AI tool can be used to triage radiology scans with intracranial bleeds, mass effect, midline shift, and cranial fractures. Two of these capabilities – cranial fractures and midline shift – are exclusive to Qure.ai’s product. This means that the newly cleared qER suite will be able to triage nearly all critical markers visible on routine head CT scans.Every year, over 75 million CT scans are performed in the US, and more than 10,000 people die within 7 days of an emergency room discharge. There is, therefore, a clear need for a comprehensive and high-quality imaging AI tool to assist healthcare providers with prioritization and image interpretation.“Our target turnaround time for emergent studies is 30 minutes but leveraging AI for acutely critical conditions enables us to shorten that time. For conditions such as intracranial hemorrhage, time is of the essence and those precious minutes can be life-changing for our patients. We have done extensive&nbsp;validation&nbsp;of the Qure.ai qER solution and are excited to continue to partner with Qure.ai and improve care for our patients” says&nbsp;Benjamin W. Strong, MD, Chief Medical Officer of vRad, the leading teleradiology services provider in the United States.

“Patient outcomes depend directly on the onset-to-treatment time, especially for brain injuries. Every day doctors are required to weigh the benefits of a potentially life-saving surgery versus the risks of an intracranial bleed or other complication. The sooner they have in-depth information that helps them make that decision, the better for the patient. This is where qER plays a key role. We wanted to offer a comprehensive solution to the clinicians, rather than a partial one that triages on the basis of limited or even single findings.”&nbsp;said Pooja Rao, Co-founder and R&amp;D head, Qure.ai.

qER plugs directly into the radiology workflow and prioritizes critical cases on the worklist. This triage drastically reduces the time taken to open critical scans, so those with time-sensitive markers get to be read and reported faster, leading to better patient outcomes. The qER product has undergone extensive validation including a 2018 peer-reviewed publication in&nbsp;The Lancet&nbsp;and has been actively deployed at many hospitals and teleradiology providers globally.

small_12.webp

thumbnail_12.webp

12.webp

Qure.ai bags industry’s first 4-in-1 FDA clearance for medical imaging AI

Qure.ai has achieved a significant milestone by receiving its inaugural US FDA 510(k) clearance for its pioneering head CT scan tool, 'qER.' This sanction enables the AI-powered solution to effectively triage radiology scans and diagnose intracranial bleeds, mass effect, midline shift, and cranial fractures. The product can uniquely detect cranial fractures and midline shifts, offering a near-comprehensive triaging solution for critical markers on regular head CT scans.

Given the high frequency of CT scans performed in the US each year, this powerful, high-grade imaging AI tool is crucial in aiding healthcare professionals to prioritize and interpret images swiftly and accurately. "The qER plays an instrumental role in providing in-depth information to doctors for making timely, crucial decisions, especially in the context of brain injuries," said Pooja Rao, Co-founder, and R&amp;D Head at Qure.ai.

The qER suite is designed to seamlessly blend with the existing radiology workflow, prioritizing critical cases and facilitating quicker and more efficient reporting of time-sensitive health markers. Having undergone rigorous validation and testing, it is now operational at several hospitals and teleradiology providers worldwide.

In addition, Qure.ai's product range also comprises the CE-marked chest X-ray AI tool qXR and COVID-19 progression monitoring solutions for chest X-rays, which are currently in clinical use across more than 20 countries.

thumbnail_AuntMinnie-logo.webp

AuntMinnie-logo.webp

Qure.AI gets FDA clearance for head CT AI software

In the midst of India's relentless battle against the COVID-19 pandemic, the Action Covid-19 Team (ACT) Grants has emerged as a beacon of hope, delivering over 3.5 million testing kits across eight states. This remarkable achievement is a testament to the power of collaboration and innovation in the face of an unprecedented global health crisis.

Established by a group of venture capital partners and the start-up community, ACT Grants has amassed a substantial fund of Rs 100 crore to support initiatives aimed at combating the spread of the virus. The grant's reach extends to 22 Indian states, where it has forged partnerships with renowned companies such as 1MG, Housejoy, and Healthians. These collaborations have been instrumental in facilitating the collection of over 50,000 samples, showcasing the grant's commitment to expanding testing capabilities and reach.

One of the most notable aspects of ACT Grants' approach is its emphasis on innovation. The partnering companies have pioneered creative solutions to enhance the accessibility and efficiency of testing, such as home sample collection, mobile clinics, and protective booths. These groundbreaking initiatives have not only increased the convenience and safety of testing but have also played a crucial role in identifying and isolating positive cases, thereby curbing the spread of the virus.

In addition to its testing efforts, ACT Grants has also garnered support from Qure.ai, a leading healthcare technology company. Qure.ai has made a significant contribution to the fight against COVID-19 by performing chest scans for over 6,000 patients. These scans have proven invaluable in aiding the detection and treatment of the virus, providing healthcare professionals with critical insights into the progression of the disease and enabling them to make informed decisions regarding patient care.

The impact of ACT Grants extends beyond its immediate partnerships and initiatives. As a coalition of top venture capitalists, founders, and industry veterans, the grant serves as a catalyst for tech-driven solutions to the COVID-19 crisis. By providing substantial funding to promising projects, ACT Grants aims to seed and empower teams that have the potential to create a large-scale impact on the detection, prevention, and eradication of the virus.

Moreover, ACT Grants offers more than just financial support. The coalition recognizes the importance of guidance, mentorship, and resources in ensuring the success of the funded initiatives. By leveraging the expertise and networks of its members, ACT Grants provides the necessary support to help these projects scale and achieve their goals. This holistic approach not only maximizes the impact of the grant but also fosters a culture of innovation and collaboration within the Indian start-up ecosystem.

The significance of ACT Grants' work cannot be overstated. In a country as vast and diverse as India, the challenges posed by the COVID-19 pandemic are immense. By focusing on expanding testing capabilities, promoting innovation, and supporting tech-driven solutions, ACT Grants is making a tangible difference in the fight against the virus. The grant's partnerships with companies like 1MG, Housejoy, Healthians, and Qure.ai demonstrate the power of collective action and highlight the critical role that the private sector can play in addressing public health crises.

As India continues to grapple with the ongoing pandemic, initiatives like ACT Grants offer hope and inspiration. By bringing together the brightest minds and most innovative companies, the grant is not only helping to mitigate the immediate impact of the virus but also laying the foundation for a more resilient and prepared healthcare system in the future.

The Action Covid-19 Team (ACT) Grants' delivery of over 3.5 million testing kits across eight states is a remarkable achievement that showcases the power of collaboration, innovation, and tech-driven solutions in the fight against COVID-19. Through its partnerships, funding, and support, ACT Grants is making a significant contribution to India's ongoing battle against the pandemic, offering a glimmer of hope in these challenging times.

small_22-1.webp

thumbnail_22-1.webp

22-1.webp

Start-up community helps in COVID-19 testing; supplies over 3.5 million kits

<a href="https://www.forbes.com/sites/markminevich/2020/06/25/15-companies-that-are-saving-the-world-from-covid-19/?sh=3d0ac1455986">Artificial Intelligence (AI) companies</a> globally are stepping up their game to combat the COVID-19 pandemic. One notable company is Airspace Systems, which has released software that monitors social distancing and face-mask compliance without using facial recognition.

Another trailblazer, BlueDot, developed outbreak risk software that alerted customers about the unusual pneumonia cases in Wuhan, China, nine days before WHO's first warnings. Also, AIDoc has received US FDA approval for its CT scanning capabilities that detect and prioritize incidental CT findings related to COVID-19.

Furthermore, Diagnostic Robotics has developed a digital triage system enabling swift containment measures. At the same time, ZOE has partnered with researchers to create an AI diagnostic tool predicting the likelihood of having COVID-19 based on symptoms. Benevolent AI used automated language tools in the pharmaceutical sector to identify potential drugs for treating COVID-19.

Meanwhile, Traces uses AI to trace the coronavirus through non-face physical traits. Cotiviti's Covid-19 Outbreak Tracker predicts potential hidden hotspots. Apixio's AI analyzes unstructured medical data for risk adjustment, and Insilico is using AI to design molecules targeting the viral protein of COVID-19. Lastly, Qure.ai's chest x-ray product, qXR, received CE certification for detecting common lung health markers, including COVID-induced pneumonia.

small_12-1.webp

thumbnail_12-1.webp

12-1.webp

Companies That Are Saving The World From Covid-19

The India Health Fund (IHF), a joint initiative of <a href="https://www.businesstoday.in/industry/pharma/story/tata-trusts-backed-india-health-fund-to-promote-start-ups-developing-means-to-fight-diseases-like-covid19-261156-2020-06-13">Tata Trusts</a> and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, plans to expand its investment to promote start-ups battling infectious diseases. By raising over Rs 2,000 crores in the next 4-5 years, IHF aims to foster innovation in diagnostic and surveillance technologies. "COVID-19 is an eye-opener to create an ecosystem and scalable platform technologies for diagnosing and monitoring infectious diseases," Madhav Joshi, CEO of IHF, stated.

Currently, IHF supports six start-ups focusing on tuberculosis and malaria and has identified six more for seed funding. Among these are Molbio Diagnostics, which has created a portable PCR diagnostics kit, and Qure.ai, which develops AI tools for lung health diagnoses. Its chest X-ray tool, qXR, is now utilized for COVID-19 patient monitoring.

Another IHF-supported venture, Valetude Primus Healthcare, has developed an efficient device for tuberculosis diagnosis. IHF's strategy is to foster innovations that address existing health challenges and can be potentially adapted for COVID-19 and other diseases.

small_28-1.webp

thumbnail_28-1.webp

28-1.webp

Tata Trusts-backed India Health Fund to promote start-ups developing means to fight diseases like COVID-19

To counter the chronic shortage of radiologists in populous countries like India, Qure.ai, a start-up founded in 2016 by Prashant Warier and Dr. Pooja Rao, is harnessing the power of <a href="https://www.entrepreneur.com/en-in/technology/this-indian-start-up-is-using-ai-to-monitor-covid-19/351294">artificial intelligence (AI) </a>to interpret radiology scans accurately. Utilizing a database of over seven million scans, their AI can evaluate images within seconds.

The company recently modified its algorithms to detect 19 chest markers, including the novel Coronavirus progression within a patient. This solution, called qXR, analyzes a chest X-ray in a minute, helping healthcare providers in areas like India prioritize patients who need immediate attention, relieving pressure on healthcare infrastructures and costs.

The software quantifies lung damage to generate a COVID-19 score indicating whether a patient is high-, medium-, or low-risk for COVID-19. Presently deployed in seven countries, qXR can determine who needs a swab test and could aid in developing therapeutic approaches to fight the disease.

Qure.ai also offers qScout, a chatbot that remotely monitors patients' symptoms and suggests future actions. From 8-10 sites a year ago, the company operates in over 70 locations across more than 25 countries.

small_5-1.webp

thumbnail_5-1.webp

5-1.webp

This Indian Start-Up Is Using AI To Monitor COVID-19 Progression Inside Patients

In response to the urgent needs of clinicians battling COVID-19, Qure.ai has quickly repurposed its AI tools to interpret lung scans. The company's chest X-ray tool, qXR, uses data from 2.5 million scans to detect lung markers for disease, with recent updates enabling it to provide a COVID-19 risk score.

Chiranjiv Singh, Qure.ai’s chief commercial officer, stated that these AI tools are crucial in assisting critical decisions about patient care, especially where there are testing shortages. The COVID-19 version of the tool is already in use at about 50 global locations, including hospitals in the U.K., India, Italy, and Mexico, and by healthcare workers in Pakistan tracking community cases.

An <a href="https://blogs.nvidia.com/blog/2020/05/28/qure-ai-covid-lung-scans/?ncid=so-twit-58357#cid=ix03_so-twit_en-sg">NVIDIA </a>Inception program member, Qure.ai employs NVIDIA TITAN GPUs on-premises and V100 Tensor Core GPUs through Amazon Web Services for training and inference of its AI models. Qure.ai is seeking FDA clearance for qXR, which already holds the CE mark in Europe.

Its qXR tool provides clinicians with a COVID-19 risk score in under a minute, while quantifying lung lesions. Its efficient, integrated workflow with existing healthcare systems has enabled it to rapidly adapt to the escalating COVID-19 crisis.

small_11.webp

thumbnail_11.webp

11.webp

Qure Helps Clinicians Answer Questions from COVID-19 Lung Scans

As COVID-19 continues to challenge global healthcare systems, Artificial Intelligence (AI) has emerged as a critical technology in the fight against the pandemic. Biotech companies worldwide leverage AI for drug repurposing, clinical trials, data analysis, and patient medical assessments.

AI's capabilities include rapid analysis of large data volumes and predictive modeling, accelerating research and development. Innovators like BenevolentAI are using AI to identify existing drugs that could treat COVID-19, while others, like Iktos and SRI International, are focusing on new drug candidates.

Amid the crisis, AI's ability to rapidly generate actionable information has increased acceptance within the biotech industry. Ronald Dorenbos, the founder of <a href="https://www.genengnews.com/gen-edge/covid-19-puts-spotlight-on-artificial-intelligence/">BioFrontline</a>, highlights the diminishing conservatism towards AI. At the same time, Russ Altman of Stanford Institute underscores the potential of machine learning in drug interaction prediction and 3D structure modeling.

India-based Qure.ai's 'AI-Powered Pandemic Response' provides tools for screening chest X-rays and mapping COVID-19 hotspots. This rapid adoption and application of AI can potentially reshape the future of healthcare, emphasizing its significance in treating and controlling pandemics.

small_11-1.webp

thumbnail_11-1.webp

11-1.webp

COVID-19 Puts Spotlight on Artificial Intelligence

<a href="https://www.theboltonnews.co.uk/news/18433436.radiologist-reveals-ai-helping-royal-bolton-hospital-fight-coronavirus/">Royal Bolton Hospital</a> in the UK is harnessing artificial intelligence (AI) in a groundbreaking approach to monitor and diagnose COVID-19 infections, using chest X-rays to track the progression of the disease. The hospital, the first in the UK to adopt this method, is employing Qure.ai's advanced diagnostic software.

According to Dr. Rizwan Malik, this technology expedites physicians' decision-making processes regarding treatment, providing objective, real-time data on lung damage and other health parameters. This additional layer of information can help indicate a patient's COVID-19 risk level based on the extent of lung damage.

The AI-assisted process bolsters the physician's diagnostic capability, providing immediate insights but does not substitute their medical expertise. It supports a more thorough diagnosis than a blood test or swab could reveal about lung health.

AI's application isn't limited to COVID-19 alone. It's also been successfully used to detect tuberculosis, cancer, and pneumonia and can be repurposed post-pandemic. Dr. Malik expressed optimism regarding this integration of AI into their team, emphasizing its ability to provide the proper care amid the ongoing global health crisis.

small_19-1.webp

thumbnail_19-1.webp

19-1.webp

Radiologist reveals how AI is helping Royal Bolton Hospital to fight coronavirus

Qure.ai's AI-powered tool, qXR, has successfully been repurposed to aid in detecting and monitoring COVID-19 progression using chest X-rays (CXRs). <a href="https://thehealthcareblog.com/blog/2020/05/07/can-ai-and-radiographs-help-in-resource-poor-areas-in-the-fight-against-covid-19/">This advanced technology</a> has been validated on a test set of 11,479 CXRs, including 515 PCR-confirmed COVID-19 cases, with an area under the curve (AUC) of 0.9, making it a promising tool in triage and ongoing monitoring of infected patients.

The tool is currently in use at over 28 global sites, where it assists in patient management amid an overwhelming demand for diagnostic resources. Apart from detecting the virus, qXR also uniquely quantifies the region affected by the infection, allowing for better monitoring of disease progression and response to treatment.

With the potential to complement existing PCR tests, qXR provides a valuable tool in settings with limited diagnostic resources. The AI-powered device can rapidly and extensively support population screening, especially when clinical suspicion of COVID-19 is high. As the world races to contain the virus, AI advancements like qXR could prove instrumental in managing the pandemic and relieving pressure on healthcare systems.

thumbnail_27.webp

27.webp

Can AI and radiographs help in resource-poor areas for the fight against COVID-19?

As the world grapples with the ongoing Covid-19 pandemic, <a href="https://www.bbc.com/news/business-52483082">artificial intelligence (AI) tools are being rapidly adopted</a> and tested worldwide. The AI algorithm, developed by Axial AI, has been instrumental in analyzing CT scans, helping physicians in Wuhan, China, ascertain the severity of viral pneumonia in patients. Currently being trialed in a Malaysian hospital, the tool has offered significant potential for tracking patients' progress.

Meanwhile, in the UK, NHS hospitals are starting to roll out AI for quicker interpretation of chest X-rays. At the Royal Bolton Hospital, an AI system trained on more than 2.5 million X-rays has been employed, assisting clinicians in making critical decisions about patient care. The system, developed by Qure.ai, is entirely housed within the hospital's network, ensuring data privacy.

As these tools emerge, calls for thorough assessment via randomized trials are increasing. While AI has the potential to expedite analysis and treatment plans, experts stress the importance of verifying the reliability and effectiveness of these technologies, as patient lives are at stake.

small_15-1.webp

thumbnail_15-1.webp

15-1.webp

The groundbreaking way to search lungs for signs of Covid-19

AI health tech company Qure.ai has made a significant stride in its mission to revolutionize healthcare by partnering with Bolton NHS Foundation Trust to deploy its cutting-edge COVID-19 monitoring software. This groundbreaking collaboration, the first of its kind in the U.K., marks a crucial step towards harnessing the power of artificial intelligence to combat the ongoing pandemic and improve patient outcomes.

Qure.ai's innovative software is designed to interpret the progression of COVID-19 through the analysis of chest X-rays, providing invaluable quantitative data in less than a minute. This rapid and accurate assessment enables clinicians to classify patients into priority categories based on the severity of their condition, allowing for more effective monitoring of disease progression and targeted allocation of medical resources.

The potential impact of this technology on patient care cannot be overstated. By aligning clinical signs with radiological images, Qure.ai's software offers a comprehensive view of a patient's condition, empowering clinicians to make more informed treatment decisions. Prashant Warier, CEO and cofounder of Qure.ai, emphasizes the significance of this capability, stating that it could potentially enhance patient treatment decisions and optimize clinical outcomes.

While the software is not intended to replace the expertise and judgment of clinicians, it serves as an additional layer of valuable data to support their decision-making process. By providing objective and quantifiable insights, Qure.ai's technology complements the skills and experience of healthcare professionals, enabling them to deliver more personalized and effective care to COVID-19 patients.

The collaboration between Qure.ai and Bolton NHS Foundation Trust is a testament to the growing recognition of the transformative potential of AI in healthcare. With the software already being utilized at 40 sites worldwide, this partnership presents Qure.ai with a unique opportunity to showcase its capabilities within the U.K. healthcare system, which is known for its commitment to innovation and excellence in patient care.

The deployment of Qure.ai's COVID-19 monitoring software at Bolton NHS Foundation Trust is expected to yield valuable insights and learnings that can inform the broader adoption of AI-powered solutions in the fight against the pandemic. By demonstrating the tangible benefits of this technology in a real-world setting, Qure.ai aims to inspire further collaborations and drive the widespread integration of AI in healthcare delivery.

Moreover, the partnership highlights the importance of collaboration between technology companies and healthcare providers in addressing the complex challenges posed by COVID-19. By bringing together the expertise of Qure.ai's team of data scientists, engineers, and medical professionals with the clinical knowledge and experience of Bolton NHS Foundation Trust, this collaboration exemplifies the power of interdisciplinary collaboration in driving innovation and improving patient outcomes.

As the world continues to grapple with the unprecedented challenges of the COVID-19 pandemic, the adoption of AI-powered solutions like Qure.ai's monitoring software offers a glimmer of hope in the quest for more effective and efficient healthcare delivery. By leveraging the power of artificial intelligence to support clinicians in their decision-making and optimize patient care, Qure.ai is at the forefront of a new era in healthcare, one that promises to transform the way we diagnose, treat, and manage diseases.

The partnership between Qure.ai and Bolton NHS Foundation Trust represents a significant milestone in the integration of AI in healthcare, particularly in the context of the COVID-19 pandemic. By deploying its cutting-edge monitoring software, Qure.ai is not only demonstrating the immense potential of AI in enhancing patient care but also setting the stage for further collaborations and innovations in the U.K. healthcare system and beyond. As we look to the future, it is clear that AI will play an increasingly crucial role in shaping the landscape of healthcare delivery, and Qure.ai is poised to be at the forefront of this transformative journey.

Qure.ai Deploys AI Radiology Software In The Fight Against COVID-19

<a href="https://www.forbesindia.com/article/coronavirus/ventures-versus-the-virus-7-indian-startups-fighting-the-pandemic/58989/1">Indian startups</a> exhibit resilience and adaptability amidst the widening coronavirus crisis, characterized as a black swan event with severe global repercussions. Gurugram's AI-focused startup has repurposed its technology for prison monitoring, enabling it to recognize coughing patients on mobile phones, providing a unique solution for hospitals short on staff.

Similarly, Asimov Robotics from Kerala has reoriented its services to assist in healthcare. Its creation, the Karmi-bot, delivers meals and medication to patients, minimizing human contact and potential virus transmission. The robot, programmed to follow a sequence of beds, provides services while ensuring patient interaction through a screen interface.

A Mumbai-based sanitary product manufacturer, identifying the shared raw materials between their products and surgical masks, shifted their production to aid in mask shortages.

Qure.ai, an AI and machine learning-based startup, utilized its pre-existing X-ray analysis software to aid in preliminary COVID-19 testing. The system is being proposed for use in mobile vans for door-to-door testing.

Despite the pandemic's challenges, Indian startups are navigating the crisis with innovative solutions and strategies.

small_9-2.webp

thumbnail_9-2.webp

9-2.webp

Ventures versus the virus 7 Indian startups fighting the pandemic

Qure.ai has confirmed its innovative diagnostic software deployment at <a href="https://www.mobihealthnews.com/news/bolton-nhs-partners-qureai-monitoring-covid-19-patients">Bolton NHS Foundation Trust in the U.K. </a>

The software expedites and automates the interpretation of chest X-rays for COVID-19, simplifying the tracking of the virus's progression for healthcare workers.

Bolton NHS Foundation Trust, which provides patient care at the Royal Bolton Hospital and other health facilities, will use Qure.ai's solution, qXR. 

This CE-certified, automated chest X-ray interpretation tool can detect findings indicative of COVID-19 and quantify the infection volume, addressing the time-consuming challenge of tracking the virus's spread in patients' lungs.

The deployment comes as tech companies worldwide develop solutions to support healthcare practitioners during the pandemic. U.S. vendors Thirona and Delft Imaging introduced CAD4COVID, an A.I. tool that analyzes X-ray images to aid healthcare specialists, and China's Ping An rolled out its COVID-19 innovative image-reading system.

In February, Qure.ai secured $16M in funding led by Sequoia India to facilitate geographical and product expansion and regulatory clearances.

Fiona Noden, Chief Executive of Bolton NHS Foundation Trust, applauded the incorporation of the latest technology in their fight against COVID-19. 

At the same time, Prashant Warier, CEO and Co-Founder of Qure.ai, highlighted the tool's ability to localize lesions, providing a COVID-19 score for prioritizing patients and quantifying disease progression.

small_26-2.webp

thumbnail_26-2.webp

26-2.webp

 Bolton NHS partners with Qure.ai for monitoring of COVID-19 patients

The COVID-19 pandemic has brought about a significant shift in the healthcare industry, with artificial intelligence (AI) taking center stage in assisting overworked healthcare professionals, particularly radiologists. The adoption of AI-based tools has seen a remarkable surge during this challenging period, proving to be a valuable asset in streamlining radiology workflows and improving patient care.

Rizwan Malik, the lead radiologist at the Royal Bolton Hospital, recognized the immense potential of AI in radiology and took proactive steps to incorporate these cutting-edge tools into his department's operations. Malik's vision was to harness the power of AI to reduce patients' wait times and enhance the efficiency of radiology services. To achieve this goal, he initiated a trial to evaluate the effectiveness of qXR, an AI-powered solution developed by Qure.ai, a Mumbai-based firm specializing in healthcare technology.

The qXR tool, designed to provide second opinions on chest X-rays, showed promising results in its initial implementation. However, as the COVID-19 pandemic swept across the United Kingdom, the trial took on a new level of urgency. Malik and his team quickly adapted qXR to detect COVID-induced pneumonia, a critical development that allowed radiologists to triage patients more effectively amidst the shortage of PCR tests. This swift adaptation of AI technology demonstrated the flexibility and responsiveness of these tools in the face of unprecedented challenges.

The success of qXR in the Royal Bolton Hospital is just one example of how AI is transforming healthcare practices worldwide. As healthcare facilities grapple with the overwhelming demands of the pandemic, AI-based solutions have emerged as a lifeline, enabling healthcare professionals to make more informed decisions, streamline workflows, and provide timely care to patients in need.

However, the rapid adoption of AI in healthcare during the pandemic has also raised concerns among experts. The urgency to deploy AI tools quickly has led to the risk of using unvetted or insufficiently tested solutions, which could potentially compromise patient safety. It is crucial for healthcare organizations to exercise caution and due diligence when implementing AI technologies, ensuring that they have undergone rigorous validation and meet the highest standards of accuracy and reliability.

Despite these challenges, the COVID-19 pandemic has undeniably served as a catalyst for the widespread adoption of AI in healthcare. The crisis has highlighted the immense potential of AI in augmenting human expertise, optimizing resource allocation, and improving patient outcomes. For AI firms operating in the healthcare sector, this accelerated adoption has opened up unprecedented opportunities for growth and innovation.

As the world continues to navigate the complexities of the pandemic, the role of AI in healthcare is expected to expand further. The lessons learned from the rapid deployment of AI tools during this crisis will shape the future of healthcare delivery, paving the way for more sophisticated and integrated AI solutions. Healthcare organizations and AI firms must work together to ensure that the adoption of AI is guided by principles of safety, transparency, and ethical considerations.

The COVID-19 pandemic has served as a turning point for AI adoption in healthcare, particularly in the field of radiology. The success stories, like that of the Royal Bolton Hospital and Qure.ai's qXR tool, demonstrate the transformative potential of AI in enhancing patient care and supporting healthcare professionals during challenging times. As we move forward, it is essential to strike a balance between the rapid adoption of AI and the need for thorough validation and oversight, ensuring that the benefits of these technologies are realized while prioritizing patient safety and well-being.

small_7-1.webp

thumbnail_7-1.webp

7-1.webp

Doctors are using AI to triage covid-19 patients. The tools may be here to stay

In a quest to curb tuberculosis (TB), the world's deadliest infectious disease, the <a href="https://www.stoptb.org/news/four-projects-innovating-path-to-end-tb">Stop TB Partnership's TB REACH initiative</a> fosters innovation. In recognition of World Creativity and Innovation Day, TB REACH shares some groundbreaking projects being funded with the support of Global Affairs Canada, USAID, the Bill, and Melinda Gates Foundation, and the Indonesia Health Fund.

Among these, a Flying Pharmacy project in Madagascar, in collaboration with Stony Brook University and the Pasteur Institute of Madagascar, uses drones to transport sputum samples and medications efficiently, transcending infrastructural obstacles and minimizing patient travel times.

Two additional TB REACH projects in the Republic of the Marshall Islands and Vietnam employed mass screenings and community mobilization, treating over 3000 people for TB and its infection. Another ongoing project in India, backed by PATH, leverages artificial intelligence and the TrueNat molecular test for rapid TB screening and diagnosis.

Moreover, TB REACH supports CIDRZ in Zambia in exploring cutting-edge diagnostic tools for childhood TB, such as a handheld X-ray camera and the FujiLAM diagnostic test. These initiatives emphasize creativity and innovation as integral to ending TB.

small_51.webp

thumbnail_51.webp

51.webp

Four projects innovating the path to end TB

The apex committee for COVID-19 response and management in <a href="https://www.forbesmiddleeast.com/preview/blogs/omans-ministry-of-health-launches-tarassud?hash=U2FsdGVkX1+a4eyXxAknHg463WcrmWAIpU9+3aGT8CQSAF2jPitYhpnKp3wRaQmF">Oman</a> has launched Tarassud+, a new advanced health monitoring platform. This was announced in collaboration with the Ministry of Interior and Technology and Communication. The venue, an upgrade of the current Tarassud system, utilizes artificial intelligence (AI) to track, diagnose, and follow up on the health of individuals infected with COVID-19 or under quarantine.

Two primary systems make up the Tarassud+ platform. The first is qScout, a contact monitoring and remote triaging program developed by Qure.ai and Al Burkan Company. This AI-powered platform allows for daily monitoring and prioritization of COVID-19 cases, reducing the burden on healthcare facilities.

The second is hMushrif, a medical supervision system developed by eMushrif. It tracks quarantined individuals using a mobile application and a wearable bracelet. The bracelet reports location data and alerts authorities in case of non-compliance with quarantine rules. The bracelet also interfaces with a facial recognition system to automatically identify quarantined individuals.

The system is also integrated with the initial Tarassud system, allowing it to monitor all COVID-19 cases across public and private healthcare centers.

Omans Ministry of Health launches Tarassud+

A recent survey of tech experts suggests that the coronavirus pandemic is poised to significantly accelerate innovation in areas such as the future of work, data and AI, trust in supply chains, and health and medicine. The majority of the 100 experts consulted indicated that the most transformative innovations over the next two to five years are likely to arise from advancements in data analytics, AI, and health technologies.

As COVID-19 places immense pressure on healthcare systems, disrupts international supply chains, and reshapes work environments, these challenges are expected to drive new waves of innovation. The previous stigma around remote work has rapidly dissolved, with remote work now widely embraced. However, the current crisis has also revealed the rigidity of existing supply chains, prompting a reassessment of their adaptability and resilience.

Artificial intelligence has played a critical role in responding to the crisis, gaining recognition for its potential benefits. For instance, healthcare AI startup Qure.ai has expanded its AI-based chest X-ray automation to enhance COVID-19 detection capabilities, while KPMG has utilized AI tools to analyze contractual obligations and termination clauses amid supply chain disruptions. Despite the long-term challenges posed by the pandemic, its influence in steering technological progress is undeniable.

Ways The Covid-19 Crisis Has Opened Minds About Technology

<a href="https://www.path.org/articles/path-fights-covid-19-india/">Amid India's surge in COVID-19 cases, PATH</a>, an international health organization, is joining forces with Qure.ai, a Mumbai-based AI tech company, to bolster the country's response to the pandemic. PATH's mission supports health equity in low-resource communities and emerging markets globally and supports India during this crisis.

Qure.ai has pivoted its existing technologies to tackle the pandemic, developing two essential tools: qXR and qSCOUT. The qXR platform, initially designed to detect tuberculosis, can interpret chest X-rays in about a minute, identifying lung characteristics indicative of COVID-19. qXR has already been deployed in Italy, the Philippines, and Southeast Asia.

Complementing qXR is qSCOUT, a contact tracing app retooled for COVID-19 that aids in patient registration, remote monitoring, and hotspot mapping to optimize supply chain and test kit distribution.

Simultaneously, PATH is aiding in managing travel and case tracking information and strengthening laboratory systems. Through a collaborative approach, PATH and Qure.ai reinforce India's health system in its battle against COVID-19.

small_33-1 (1).webp

thumbnail_33-1 (1).webp

33-1 (1).webp

With technology, information, and staff, PATH fights COVID-19 in India

Medical imaging technology firm, Nanox, has recently announced a strategic partnership with AI software developer, Qure.ai, in a move that is set to revolutionize the medical imaging industry. This collaboration aims to fortify Nanox's upcoming Nanox.Cloud software platform by integrating Qure.ai's cutting-edge artificial intelligence capabilities, creating a powerful tool that will enhance the efficiency and accuracy of medical diagnosis.

Qure.ai, renowned for its innovative software applications, has made significant strides in the field of medical AI. Their solutions have been specifically designed to streamline the process of chest X-ray screening and head CT scans, enabling healthcare professionals to make more informed decisions in a shorter amount of time. By incorporating Qure.ai's tools into the Nanox.Cloud platform, Nanox aims to create a comprehensive and robust system that will empower healthcare providers to deliver better patient care.

The integration of Qure.ai's AI algorithms into the Nanox.Cloud platform is expected to significantly enhance its functionalities. The combined strengths of these two technologies will allow for more accurate and efficient analysis of medical images, reducing the likelihood of missed diagnoses and improving overall patient outcomes. Healthcare professionals using the platform will have access to a wealth of information and insights, enabling them to make more informed decisions and provide personalized treatment plans.

Moreover, this partnership underscores the growing trend of increased reliance on AI in the healthcare industry. As medical technology continues to advance at a rapid pace, the potential for AI to transform the way we approach diagnosis and treatment is becoming increasingly evident. By harnessing the power of machine learning and deep neural networks, AI-powered tools can analyze vast amounts of medical data, identifying patterns and anomalies that may be difficult for human eyes to detect.

The collaboration between Nanox and Qure.ai is a testament to the commitment of both companies to drive innovation in the field of medical technology. By pooling their expertise and resources, they are pushing the boundaries of what is possible, developing cutting-edge solutions that have the potential to address some of the most pressing global health challenges.

One of the key benefits of this partnership is the potential for increased accessibility to advanced medical imaging technology. Nanox's mission is to make medical imaging more affordable and widely available, particularly in underserved regions where access to such technology is limited. By integrating Qure.ai's AI capabilities into the Nanox.Cloud platform, the company is taking a significant step towards realizing this vision, empowering healthcare providers in even the most remote areas to deliver high-quality care.

Furthermore, the integration of AI into medical imaging has the potential to reduce healthcare costs and improve efficiency. By automating certain tasks and providing healthcare professionals with more accurate and timely information, AI-powered tools can help streamline workflows and reduce the need for unnecessary tests and procedures. This, in turn, can lead to significant cost savings for healthcare systems and improve the overall quality of care for patients.

As the partnership between Nanox and Qure.ai moves forward, it will be exciting to see how their combined efforts will shape the future of medical imaging. The integration of AI into the Nanox.Cloud platform is just the beginning, and there is no doubt that this collaboration will pave the way for further innovations in the field.

In conclusion, the strategic partnership between Nanox and Qure.ai represents a significant milestone in the integration of AI and medical imaging technology. By combining their strengths and expertise, these two companies are driving innovative solutions that have the potential to transform the way we approach healthcare, improving diagnosis and treatment outcomes on a global scale. As the healthcare industry continues to evolve, collaborations like this will be essential in addressing the complex challenges we face and ensuring that everyone, regardless of their location or socioeconomic status, has access to the highest quality medical care.

Nannox Partners with Qure

As the global Covid-19 cases surpass the staggering milestone of 12 million, countries worldwide find themselves grappling with an acute shortage of testing kits. This scarcity has put immense pressure on healthcare systems, forcing them to make difficult decisions about who gets tested and when. In response to this pressing challenge, Qure.ai, a renowned leader in healthcare technology, has pioneered an AI-backed solution that could revolutionize the way testing priorities are determined amidst such scarcity.

The innovative approach introduced by Qure.ai leans on the fundamental principle of medical triaging, a process that involves categorizing patients based on the severity of their illnesses or wounds. Triaging has long been a cornerstone of emergency medicine, enabling healthcare professionals to make quick and informed decisions about the order in which patients should receive treatment. By applying this principle to the context of Covid-19 testing, Qure.ai aims to streamline the testing process among large populations and identify individuals who require immediate attention.

At the heart of Qure.ai's cutting-edge technology lies the power of artificial intelligence. The company has developed a sophisticated AI algorithm that can interpret X-rays with remarkable accuracy. By analyzing chest X-rays of potential Covid-19 patients, the AI system can detect signs of lung abnormalities associated with the virus, such as ground-glass opacities and consolidations. This information is then used to classify patients into three risk categories: high, medium, and low.

The classification of patients based on their risk level is a game-changer in the face of testing kit shortages. Healthcare professionals can utilize Qure.ai's AI-powered solution to prioritize testing procedures for those who are deemed high-risk, ensuring that the most critical cases receive immediate attention. This targeted approach not only optimizes the use of limited testing resources but also helps identify individuals who may require urgent medical intervention.

Moreover, Qure.ai's solution goes beyond just prioritizing testing. The AI algorithm can also provide valuable insights into the progression of the disease in individual patients. By comparing X-rays taken at different stages of the illness, the system can track changes in lung abnormalities over time, enabling healthcare professionals to monitor patient recovery or deterioration more effectively. This longitudinal assessment can aid in making informed decisions about treatment plans and resource allocation.

The impact of Qure.ai's AI-backed solution extends far beyond the realm of healthcare facilities. By enabling more efficient and targeted testing, the technology can help contain the spread of the virus in communities. Identifying and isolating high-risk individuals early on can break the chain of transmission, reducing the overall burden on healthcare systems and saving countless lives in the process.

As the demand for testing kits continues to outstrip supply, Qure.ai's innovative solution offers a beacon of hope in the fight against Covid-19. By harnessing the power of AI to interpret X-rays and prioritize testing procedures, the company is providing healthcare professionals with a valuable tool to navigate the challenges posed by resource scarcity. The efficient utilization of testing kits, coupled with the ability to identify high-risk patients promptly, can make a significant difference in the battle against this global pandemic.

Qure.ai's AI-backed solution for Covid-19 testing prioritization is a testament to the transformative potential of technology in healthcare. As countries worldwide continue to grapple with the unprecedented challenges posed by the virus, innovative approaches like those pioneered by Qure.ai will be instrumental in saving lives and mitigating the impact of the pandemic. By embracing the power of AI and adapting to the changing landscape of healthcare, we can work towards a future where no one is left behind in the fight against Covid-19.

small_13.webp

thumbnail_13.webp

13.webp

How Qure.ai is helping Italian doctors test Covid-19 patients

In response to the ongoing pandemic, <a href="https://inc42.com/buzz/startupsvscovid19-niti-aayog-invites-eight-startups-to-be-part-of-covid-19-committee/">India's central government</a> is working diligently to bolster the country's healthcare infrastructure. They have formed a committee, led by NITI Aayog CEO Amitabh Kant, to collaborate with private companies and startups to produce health and personal protection equipment (PPE).

The committee has hosted six meetings with various organizations since its inception on March 3. These organizations, consisting of startups, industry associations, and civil society groups, are working together to devise solutions to the healthcare challenges posed by the pandemic.

The startups involved range from AgVa, developing compact ventilators, to Qure.ai, which works on solutions to interpret chest X-rays automatically. The committee's efforts extend beyond equipment production, as the government seeks to enhance the security of its Aarogya Setu app, a tool used to keep users' data safe during the crisis.

News and Press